Dima Shulkin: A Novel Monocyte-Based Biomarker of Cardiovascular Risk
Dima Shulkin, Co-Founder and CTO at RobotDreams GmbH, shared a post on LinkedIn:
“What if a simple blood test could flag hidden heart disease long before any symptoms appear?
A 2024 medRxiv preprint by Almarri and colleagues (not yet peer-reviewed) explored exactly that.
They studied symptom-free adults, first a small group of 39, then 151 more in Nanjing, China, measuring immune cells called monocytes (part of the body’s defense team) and how often they clump with platelets.
The readings became a new score, MARS, which tracked real artery damage far more closely than the standard risk calculators doctors use now.
Early research, but a real hint that a blood sample may reveal what checklists miss.”
Other posts featuring Dima Shulkin on Hemostasis Today.
-
May 26, 2026, 09:42Wael AlAnazi: Exceptional HLA-Matched Transplant Outcomes With Novel Thiotepa-Based Conditioning
-
May 26, 2026, 09:31Vanduyn Hoven Sibarani: Impact of Pac Dosing on Raw Water Coagulation Performance
-
May 26, 2026, 09:30Sivasooriar Sivaneson: Every Drop of Blood Matters in Pre-Analytical Laboratory Quality
-
May 26, 2026, 08:11Shady Abohashem։ Stress, Hormones, and Cardiovascular Risk in Women
-
May 26, 2026, 07:39Abdulrahman Nasiri: Managing Refractory Severe Aplastic Anemia During Pregnancy
-
May 26, 2026, 07:21Eman Badr: From Platelets to Precision Oncology
-
May 26, 2026, 07:12Jenish Christin: The Clot Buster That Buys Time in Critical Moments
-
May 26, 2026, 06:43Francisco Epelde: Cardiac Lymphatic System as an Active Regulator of Myocardial Homeostasis
-
May 26, 2026, 06:39Reza Shojaei: How Neurology is Reshaping the Plasma Market?